On April 12th, 2022, InfanDx AG announced its USA operations to gain the market for its in vitro diagnostic product, HypoxE® Test. The company is involved in developing the Hypoxic-Ischemic Encephalopathy (HIE) test. Globally, around 2% of newborns show clinical symptoms of HIE.
HIE condition occurs when the brain doesn'™t receive sufficient oxygen or blood flow for a period of time. Hypoxic-Ischemic Encephalopathy can affect the brain tissue and cause severe and permanent disabilities such as developmental delay, cognitive, motor impairment, and epilepsy. In order to diagnose the HIE, the newborn will be monitored by an electroencephalogram and magnetic resonance imaging